A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Inclusion Criteria: * Male or female participants, age 18 to 75, inclusive, at the time of informed consent. * BMI between 18 and 40 kg/m2, inclusive, at Screening. * Continuous non-smokers or smokers who smoke 20 cigarettes or fewer per day. * Willingness and ability to swallow study intervention tablets. * Estimated glomerular filtration rate (eGFR) of 45 mL/minute or higher calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 creatinine equation at Screening. * Chronic and stable hepatic impairment conforming to Child-Pugh classification A, B, or C, and documented by medical history and a physical examination. * Adequate bone marrow, renal, and hepatic function at Screening. * Healthy participants matched to participants with hepatic impairment with regard to sex, BMI (±20%) and age (±10 years), and determined to have no clinically significant deviations from normal in their medical history, physical examination, ECG, and clinical laboratory determinations. Exclusion Criteria: * Participant is mentally or legally incapacitated or has significant emotional problems at the time of the Screening visit or such issues can be expected during the conduct of the study. * History of liver transplant. * History of any major invasive surgery within 28 days before dosing, or minor invasive surgery within 7 days before dosing. * Presence of any clinically significant, ongoing systemic bacterial, fungal, or viral infections (including upper respirator…